Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Acquisitions & Divestments (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $14.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Change in Acquisitions & Divestments fell 44.98% year-over-year to $14.2 million, compared with a TTM value of $94.4 million through Jun 2025, up 151.6%, and an annual FY2025 reading of $68.3 million, down 18.69% over the prior year.
  • Change in Acquisitions & Divestments was $14.2 million for Q2 2025 at VYNE Therapeutics, down from $33.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $33.6 million in Q1 2025 and bottomed at $1.0 million in Q2 2021.
  • Average Change in Acquisitions & Divestments over 3 years is $19.0 million, with a median of $22.9 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments plummeted 95.15% in 2021, then soared 189.66% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $1.0 million in 2021, then soared by 2129.8% to $22.9 million in 2024, then tumbled by 37.77% to $14.2 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for VYNE at $14.2 million in Q2 2025, $33.6 million in Q1 2025, and $22.9 million in Q4 2024.